MarketPulse

chronic myeloid leukemia

3 articles
Investing.comInvesting.com··Jessica Mitacek

Merck Bets $6.7B on Cancer Pipeline With Terns Pharmaceutical Acquisition

Merck acquires Terns Pharmaceutical for $6.7B to expand cancer pipeline with oral BCR-ABL1 inhibitor, targeting $70B commercial opportunity by mid-2030s.
MRKABBVLLYTERNacquisitiondividend growth
BenzingaBenzinga··Globe Newswire

Merck to Acquire Terns Pharmaceuticals for $6.7B to Bolster CML Portfolio

Merck acquires Terns Pharmaceuticals for $6.7 billion to gain TERN-701, a novel leukemia treatment, at 31% premium valuation.
MRKTERNacquisitionM&A
BenzingaBenzinga··Tanya Rawat

Merck to Acquire Terns Pharma for $6B, Bolstering Oncology Pipeline Before Keytruda Patent Cliff

Merck pursues $6B acquisition of Terns Pharma to strengthen oncology pipeline as Keytruda faces patent expiration amid broader $320B industry revenue cliff.
MRKNVSTERNacquisitionM&A